David Moliterno, MD — University of Kentucky
Faculty Disclosure
Nothing to Disclose
Learning Objectives
- Describe the function and action of the platelet glycoprotein (GP) IIb/IIIa receptor
- List features and characteristics that distinguish the three commercially available GP IIb/IIIa antagonists
- Summarize the relative risk reductions in ischemic events (death and myocardial infarction) provided by GP IIb/IIIa inhibitors in ACS and PCI
- List major complications with IIb/IIIa inhibitors and the percent of patients experiencing adverse events
- Describe measures used to minimize complications associated with GP IIb/IIIa inhibitors